Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 1,585 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Urinary Bladder Diseases\Urologic Diseases Clear all

Conditions: Bladder Cancer, Bladder Stone, Bladder Outlet Obstruction, Renal Stone, Renal Disease
Interventions: Cystoscopy with RedPine flexible disposable cystoscope, Cystoscopy with standard of care flexible reusable scope; Device
Lead sponsor: Guangzhou Red Pine Medical Instrument Co., Ltd.; Industry
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Hersey, Pennsylvania • Dallas, Texas • Seattle, Washington

Conditions: Solid Tumor
Interventions: Rucaparib; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 19
States / cities: Los Angeles, California • San Francisco, California • Fort Myers, Florida + 15 more

Conditions: Multiple Sclerosis
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Theodore R. Brown, MD MPH; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Kirkland, Washington

Conditions: Interstitial Cystitis
Interventions: LiRIS 400 mg, LiRIS Placebo; Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Glendora, California • Daytona Beach, Florida • Kansas City, Kansas + 12 more

Conditions: Solid Malignancies, Non-Hodgkin's Lymphoma
Interventions: AQ4N; Drug
Lead sponsor: Novacea; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 2
States / cities: The Bronx, New York • San Antonio, Texas

Conditions: Visceral Prolapse
Interventions: Open, Robotic, or Laparoscopic, Transvaginal Native Tissue Repair, Uphold™ LITE; Procedure
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 21 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Albuquerque, New Mexico + 6 more

Conditions: Bladder Cancer
Interventions: therapeutic conventional surgery, therapeutic standard lymphadenectomy, therapeutic extended lymphadenectomy; Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 29
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: VNX001; Drug
Lead sponsor: Vaneltix Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Tucson, Arizona • Fresno, California • Tustin, California + 2 more

Conditions: Locally Advanced or Metastatic Urothelial Carcinoma
Interventions: Avelumab, Sacituzumab Govitecan (SG), M6223, NKTR-255, JB100; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Coeur d'Alene, Idaho • Kansas City, Kansas • Baltimore, Maryland + 4 more

Conditions: Urothelial Carcinoma
Interventions: Rogaratinib (BAY1163877), Atezolizumab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Tucson, Arizona • Chicago, Illinois • Detroit, Michigan + 1 more

Conditions: Bladder Cancer, Biomarkers
Interventions: Collection of urine and bladder tumor specimens; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Transvaginal botulinum toxin A (BTA) injection; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Overactive Bladder
Interventions: Urgent PC Neuromodulation System; Device
Lead sponsor: Uroplasty, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 15
States / cities: Chico, California • Greenwich, Connecticut • Naples, Florida + 12 more

Conditions: Spinal Cord Injury, Acute, Neurogenic Bladder, Incontinence, Urinary Tract Infections
Interventions: PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN); Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Downey, California • Salt Lake City, Utah

Conditions: Carcinoma, Transitional Cell
Interventions: Tesetaxel; Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Bladder Cancer
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Kansas City, Kansas

Conditions: Urinary Retention, Urinary Bladder, Neurogenic, Intermittent Catheterization
Interventions: C3 "UMBRELLA CATHETER"; Device
Lead sponsor: Dr. Gaines W. Hammond Jr. MD FACS; Individual
Eligibility: 21 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lakeland, Florida

Conditions: Urge Urinary Incontinence
Interventions: Fesoterodine Fumarate; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Chronic Kidney Diseases, Bladder Dysfunction, Bladder Absence, Posterior Urethral Valve, Neurogenic Bladder, Bladder Exstrophy, Bladder Outlet Obstruction, Failure, Kidney, Transplant
Interventions: Concomitant Renal and Urinary Bladder Allograft Transplantation; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 1 Year to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Rochester, Minnesota

Conditions: Brain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, HEENT Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma, Testicular Cancer
Interventions: Stereotactic Radiosurgery; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Pulsed Electromagnetic Field (PEMF) Therapy; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Bladder Cancer
Interventions: Not listed
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Overactive Bladder
Interventions: Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator; Device
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Bladder Cancer
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Search by objective public record fields.

A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients.

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis

Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Apical Suspension Repair for Vault Prolapse In a Three-Arm Randomized Trial Design

S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma

Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder

Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome

Study of Urgent PC Versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms

Sacral Nerve Stimulation in Improving Bladder Function After Acute Traumatic Spinal Cord Injury

Tesetaxel for Previously Treated Patients With Bladder Cancer

Measuring Taste Perception During Chemotherapy for Muscle Invasive Bladder Cancer

A Prospective Evaluation of the Catheter Science C3 "Umbrella Catheter."

Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)

Concomitant Renal and Urinary Bladder Allograft Transplantation

Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases

PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome

Physical Therapy in Pre-cystectomy Patients

Neuromodulation Implantation Settings Variation for Overactive Bladder

Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)